Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Sangamo Therapeutics

Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?

CRISPR Stocks: Buy or Trade?

The pharma giant controls a massive addressable market and has proven its ability to increase drug sales.

Could Vertex Pharmaceuticals Be a Millionaire-Maker Stock?

Abbott Labs

Tandem Diabetes Care

These three stocks are among the few winners to emerge from the coronavirus stock market.

Next Coronavirus Market Crash: Where to Invest $1,000

Vertex's (VRTX) sNDAs seek approval of Trikafta, Symdeko, and Kalydeco for additional rare mutations in the CFTR genes.

Vertex Seeks Nod for Cystic Fibrosis Drugs for Rare Mutations

BOSTON--(BUSINESS WIRE)-- #cf--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) accepted three supplemental New Drug Applications (sNDAs) for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor).

FDA Accepts Vertex’s Supplemental New Drug Applications for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Additional CFTR Mutations

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?

Why Is Vertex (VRTX) Down 3.4% Since Last Earnings Report?

Is  (VRTX) Outperforming Other Medical Stocks This Year?

Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year?

Amgen

Biogen

Gilead Sciences

Incyte

Regeneron Pharmaceuticals

Biotech Industry Near-Term Outlook Modest Amid Coronavirus

ABIOMED

Bio-Rad Laboratories

Danaher

DexCom

Hologic

IDEXX Laboratories

Thermo Fisher Scientific

West Pharmaceutical Services

Savvy investors should consider adding these stocks to their portfolio to enhance its performance and diversity.

These 10 Stocks Are the Biggest S&P 500 Healthcare Winners of 2020

The short interest data are out for August 14, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Major Biotechs Scare Off Short Sellers

Vertex's (VRTX) triple combo regimen Kaftrio (ivacaftor/tezacaftor/elexacaftor) secures a nod in Europe to treat the younger lot aged 12 years and above with cystic fibrosis.

Vertex's Triple Combo Cystic Fibrosis Pill Kaftrio Gets EU Nod

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission (EC) has granted marketing authorization for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor to treat people with cystic fibrosis (CF) ages 12 years and older with one F508del mutation and one minimal function mutation (F/MF), or two F508del mutations (F/F) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. For the firs

European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and Older

Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
The post Stock Upgrades: Vertex Pharmaceuticals Shows Rising Relative Strength appeared first on Investor's Business Daily.

Stock Upgrades: Vertex Pharmaceuticals Shows Rising Relative Strength

Alexion Pharma

XBiotech

Biotech stocks are futuristic, but they're also bearing fruit now. So, check out these five hitting on trends and making investors money now.

5 Disruptive Biotech Stocks to Buy for the Future That Is Here

Provention Bio Inc

Each of these companies has the potential to generate life-changing returns.

2 Revolutionary Biotech Stocks to Buy Right Now

Advanced Micro Devices

Centene

Old National Bancorp

World Wrestling Entertainment

The US-China tensions continue to keep markets at bay, but growth companies continue to be leaders for the market overall. Our deep learning algorithms using  AI technology have rated some of Top Growth Stocks below if you're looking to invest long-term on some future prospects.

Top Growth Stocks For August

AstraZeneca

iShares Nasdaq Biotechnology ETF

Johnson & Johnson

Eli Lilly

Merck

Moderna

Novo Nordisk

Roche Holding AG

Sanofi

SPDR S&P Biotech ETF

The biotech sector had a troubled Q2, as doctor visits were curtailed and new Rx'es were in short supply; R&D efforts were also harmed.

Biotech's Q2:  Lots Of Candidates That May Deliver Alpha

The momentum is not over for this company or its blockbuster cystic fibrosis drug.

Why Vertex Pharmaceuticals Is the Best Biotech Stock to Buy in August

GW Pharmaceuticals

Some of the most promising stocks on the market right now are pharmaceuticals.

3 Pharmaceutical Stocks That Can Make You Rich

Emergent BioSolutions

These two stocks weathered the March crash without incident.

2 Rock-Solid Pharma Stocks That Won't Flinch if the Market Crashes

Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up

How Vertex Pharmaceuticals Wowed With Its Q2 Results

Vertex, Inc.

Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q2 2020 Results - Earnings Call Transcript

Vertex (VRTX) delivered earnings and revenue surprises of 22.54% and 8.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue Estimates

Vertex Pharmaceuticals late Thursday reported adjusted earnings of $2.61 per share on $1.52 billion in sales for its second quarter, both numbers well above expectations, and shares rose .
The post Vertex Stock Rises After Second-Quarter Earnings Beat Views appeared first on Investor's Business Daily.

News for Vertex Pharmaceuticals Stock (VRTX)